Skip to main content
PMC home page
The American Journal of Pathology logoLink to The American Journal of Pathology
. 1993 Mar;142(3):691–698.

An in vivo model of human multidrug-resistant multiple myeloma in SCID mice.

W T Bellamy 1, A Odeleye 1, P Finley 1, B Huizenga 1, W S Dalton 1, R S Weinstein 1, E M Hersh 1, T M Grogan 1
PMCID: PMC1886807  PMID: 8456932

Abstract

We have established a reproducible in vivo model of human multiple myeloma in the severe combined immunodeficient (SCID) mouse using both the RPMI 8226 human myeloma cell line and the P-glycoprotein-expressing multidrug-resistant 8226/C1N subline. SCID mice 5 to 8 weeks of age were injected intraperitoneally with either 8226 drug-sensitive or P-glycoprotein-expressing multidrug-resistant myeloma cells (8226/C1N). Tumors were detected within 5 days after injection by the presence of human lambda light chain excretion in the mouse urine. Growth of the tumor was observed primarily in the abdominal cavity with spread to the abdominal organs. The anti-neoplastic agent doxorubicin was effective in treating the drug-sensitive 8226 human-SCID xenografts but had no effect on the multi-drug-resistant 8226/C1N human-SCID xenografts. In the 8226-sensitive xenografts, treatment with doxorubicin resulted in a sharp decline in the concentration of human lambda light chain being excreted in the mouse urine. This correlated with an increased survival of the drug-treated animals. This mouse model offers an in vivo means of evaluating efficacy and toxicity of new therapeutic approaches, including development of chemosensitizers directed against P-glycoprotein in multidrug-resistant myelomas.

Full text

PDF
692

Images in this article

694Figure 1
on p.694

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Azar H. A. Experimental plasmacytomas in relation to human multiple myeloma. Ann Clin Lab Sci. 1974 May-Jun;4(3):157–163. [PubMed] [Google Scholar]
  2. Bellamy W. T., Dalton W. S., Kailey J. M., Gleason M. C., McCloskey T. M., Dorr R. T., Alberts D. S. Verapamil reversal of doxorubicin resistance in multidrug-resistant human myeloma cells and association with drug accumulation and DNA damage. Cancer Res. 1988 Nov 15;48(22):6365–6370. [PubMed] [Google Scholar]
  3. Bosma G. C., Custer R. P., Bosma M. J. A severe combined immunodeficiency mutation in the mouse. Nature. 1983 Feb 10;301(5900):527–530. doi: 10.1038/301527a0. [DOI] [PubMed] [Google Scholar]
  4. Bosma G. C., Davisson M. T., Ruetsch N. R., Sweet H. O., Shultz L. D., Bosma M. J. The mouse mutation severe combined immune deficiency (scid) is on chromosome 16. Immunogenetics. 1989;29(1):54–57. doi: 10.1007/BF02341614. [DOI] [PubMed] [Google Scholar]
  5. Croese J. W., Vas Nunes C. M., Radl J., van den Enden-Vieveen M. H., Brondijk R. J., Boersma W. J. The 5T2 mouse multiple myeloma model: characterization of 5T2 cells within the bone marrow. Br J Cancer. 1987 Nov;56(5):555–560. doi: 10.1038/bjc.1987.241. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Dalton W. S., Durie B. G., Alberts D. S., Gerlach J. H., Cress A. E. Characterization of a new drug-resistant human myeloma cell line that expresses P-glycoprotein. Cancer Res. 1986 Oct;46(10):5125–5130. [PubMed] [Google Scholar]
  7. Dalton W. S., Grogan T. M., Meltzer P. S., Scheper R. J., Durie B. G., Taylor C. W., Miller T. P., Salmon S. E. Drug-resistance in multiple myeloma and non-Hodgkin's lymphoma: detection of P-glycoprotein and potential circumvention by addition of verapamil to chemotherapy. J Clin Oncol. 1989 Apr;7(4):415–424. doi: 10.1200/JCO.1989.7.4.415. [DOI] [PubMed] [Google Scholar]
  8. Feo-Zuppardi F. J., Taylor C. W., Iwato K., Lopez M. H., Grogan T. M., Odeleye A., Hersh E. M., Salmon S. E. Long-term engraftment of fresh human myeloma cells in SCID mice. Blood. 1992 Dec 1;80(11):2843–2850. [PubMed] [Google Scholar]
  9. Grogan T., Dalton W., Rybski J., Spier C., Meltzer P., Richter L., Gleason M., Pindur J., Cline A., Scheper R. Optimization of immunocytochemical P-glycoprotein assessment in multidrug-resistant plasma cell myeloma using three antibodies. Lab Invest. 1990 Dec;63(6):815–824. [PubMed] [Google Scholar]
  10. Hendrickson E. A., Qin X. Q., Bump E. A., Schatz D. G., Oettinger M., Weaver D. T. A link between double-strand break-related repair and V(D)J recombination: the scid mutation. Proc Natl Acad Sci U S A. 1991 May 15;88(10):4061–4065. doi: 10.1073/pnas.88.10.4061. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Hendrix M. J., Seftor E. A., Grogan T. M., Seftor R. E., Hersh E. M., Boyse E. A., Liotta L. A., Stetler-Stevenson W., Ray C. G. Expression of type IV collagenase correlates with the invasion of human lymphoblastoid cell lines and pathogenesis in SCID mice. Mol Cell Probes. 1992 Feb;6(1):59–65. doi: 10.1016/0890-8508(92)90072-6. [DOI] [PubMed] [Google Scholar]
  12. Juranka P. F., Zastawny R. L., Ling V. P-glycoprotein: multidrug-resistance and a superfamily of membrane-associated transport proteins. FASEB J. 1989 Dec;3(14):2583–2592. doi: 10.1096/fasebj.3.14.2574119. [DOI] [PubMed] [Google Scholar]
  13. Kamel-Reid S., Letarte M., Sirard C., Doedens M., Grunberger T., Fulop G., Freedman M. H., Phillips R. A., Dick J. E. A model of human acute lymphoblastic leukemia in immune-deficient SCID mice. Science. 1989 Dec 22;246(4937):1597–1600. doi: 10.1126/science.2595371. [DOI] [PubMed] [Google Scholar]
  14. Lanier E. R., Brown R. M., Kraig E. Binding of thymic factors to the conserved decanucleotide promoter element of the T-cell receptor V beta gene is developmentally regulated and is absent in SCID mice. Proc Natl Acad Sci U S A. 1991 Sep 15;88(18):8131–8135. doi: 10.1073/pnas.88.18.8131. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Malynn B. A., Blackwell T. K., Fulop G. M., Rathbun G. A., Furley A. J., Ferrier P., Heinke L. B., Phillips R. A., Yancopoulos G. D., Alt F. W. The scid defect affects the final step of the immunoglobulin VDJ recombinase mechanism. Cell. 1988 Aug 12;54(4):453–460. doi: 10.1016/0092-8674(88)90066-9. [DOI] [PubMed] [Google Scholar]
  16. Matsuoka Y., Moore G. E., Yagi Y., Pressman D. Production of free light chains of immunoglobulin by a hematopoietic cell line derived from a patient with multiple myeloma. Proc Soc Exp Biol Med. 1967 Aug-Sep;125(4):1246–1250. doi: 10.3181/00379727-125-32327. [DOI] [PubMed] [Google Scholar]
  17. Mickisch G. H., Merlino G. T., Galski H., Gottesman M. M., Pastan I. Transgenic mice that express the human multidrug-resistance gene in bone marrow enable a rapid identification of agents that reverse drug resistance. Proc Natl Acad Sci U S A. 1991 Jan 15;88(2):547–551. doi: 10.1073/pnas.88.2.547. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Millar B. C., Millar J. L., Jones A., Feary S. W., Robertson D., Bell J. B. Activation of murine 'T' lymphomas in the presence of a human myeloma cell line, RPMI-8226, in vivo. Br J Cancer. 1988 Mar;57(3):290–292. doi: 10.1038/bjc.1988.63. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. POTTER M., BOYCE C. R. Induction of plasma-cell neoplasms in strain BALB/c mice with mineral oil and mineral oil adjuvants. Nature. 1962 Mar 17;193:1086–1087. doi: 10.1038/1931086a0. [DOI] [PubMed] [Google Scholar]
  20. Radl J., Croese J. W., Zurcher C., Van den Enden-Vieveen M. H., de Leeuw A. M. Animal model of human disease. Multiple myeloma. Am J Pathol. 1988 Sep;132(3):593–597. [PMC free article] [PubMed] [Google Scholar]
  21. Rowe M., Young L. S., Crocker J., Stokes H., Henderson S., Rickinson A. B. Epstein-Barr virus (EBV)-associated lymphoproliferative disease in the SCID mouse model: implications for the pathogenesis of EBV-positive lymphomas in man. J Exp Med. 1991 Jan 1;173(1):147–158. doi: 10.1084/jem.173.1.147. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Salmon S. E., Dalton W. S., Grogan T. M., Plezia P., Lehnert M., Roe D. J., Miller T. P. Multidrug-resistant myeloma: laboratory and clinical effects of verapamil as a chemosensitizer. Blood. 1991 Jul 1;78(1):44–50. [PubMed] [Google Scholar]
  23. Salmon S. E., Smith B. A. Immunoglobulin synthesis and total body tumor cell number in IgG multiple myeloma. J Clin Invest. 1970 Jun;49(6):1114–1121. doi: 10.1172/JCI106327. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Sonneveld P., Durie B. G., Lokhorst H. M., Marie J. P., Solbu G., Suciu S., Zittoun R., Löwenberg B., Nooter K. Modulation of multidrug-resistant multiple myeloma by cyclosporin. The Leukaemia Group of the EORTC and the HOVON. Lancet. 1992 Aug 1;340(8814):255–259. doi: 10.1016/0140-6736(92)92353-h. [DOI] [PubMed] [Google Scholar]

Articles from The American Journal of Pathology are provided here courtesy of American Society for Investigative Pathology

RESOURCES